Raymond James & Associates Alaunos Therapeutics, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	SELL	$0.04 - $0.13 $420 - $1,365	-10,500 Reduced 38.52%	16,761 $1,000
Q3 2023 Oct 24, 2023	SELL	$0.12 - $0.5 $4,077 - $16,990	-33,980 Reduced 55.49%	27,261 $3,000
Q1 2023 Apr 14, 2023	SELL	$0.46 - $0.81 $2,484 - $4,374	-5,400 Reduced 8.1%	61,241 $38,000
Q4 2022 Feb 08, 2023	BUY	$0.5 - $261.0 $214 - $111,969	429 Added 0.65%	66,641 $43,000
Q3 2022 Oct 25, 2022	SELL	$1.04 - $322.5 $7,800 - $2.42 Million	-7,500 Reduced 10.17%	66,212 $114,000
Q2 2022 Aug 12, 2022	SELL	$0.41 - $1.24 $175 - $529	-427 Reduced 0.58%	73,712 $91,000
Q1 2022 May 11, 2022	SELL	$0.62 - $1.17 $6,138 - $11,583	-9,900 Reduced 11.78%	74,139 $48,000
Q4 2021 Feb 08, 2022	BUY	$1.09 - $1.89 $1,635 - $2,835	1,500 Added 1.82%	84,039 $92,000
Q3 2021 Nov 02, 2021	SELL	$1.44 - $2.73 $10,185 - $19,309	-7,073 Reduced 7.89%	82,539 $150,000
Q2 2021 Aug 11, 2021	SELL	$2.63 - $3.67 $17,095 - $23,855	-6,500 Reduced 6.76%	89,612 $237,000
Q1 2021 May 14, 2021	SELL	$2.82 - $5.6 $9,105 - $18,082	-3,229 Reduced 3.25%	96,112 $346,000
Q4 2020 Feb 12, 2021	SELL	$2.09 - $3.09 $15,263 - $22,566	-7,303 Reduced 6.85%	99,341 $250,000
Q3 2020 Nov 04, 2020	SELL	$2.39 - $3.43 $5,157 - $7,401	-2,158 Reduced 1.98%	106,644 $269,000
Q2 2020 Jul 28, 2020	BUY	$2.2 - $3.71 $11,330 - $19,106	5,150 Added 4.97%	108,802 $357,000
Q1 2020 Apr 21, 2020	BUY	$1.9 - $4.98 $62,147 - $162,890	32,709 Added 46.11%	103,652 $254,000
Q4 2019 Feb 12, 2020	BUY	$3.95 - $5.35 $86,220 - $116,779	21,828 Added 44.44%	70,943 $335,000
Q3 2019 Nov 07, 2019	BUY	$4.13 - $6.94 $3,820 - $6,419	925 Added 1.92%	49,115 $210,000
Q2 2019 Aug 06, 2019	SELL	$3.98 - $6.2 $48,285 - $75,218	-12,132 Reduced 20.11%	48,190 $281,000
Q1 2019 May 06, 2019	BUY	$2.0 - $4.4 $8,122 - $17,868	4,061 Added 7.22%	60,322 $232,000
Q4 2018 Feb 11, 2019	SELL	$1.61 - $3.62 $2,922 - $6,570	-1,815 Reduced 3.13%	56,261 $105,000
Q3 2018 Nov 14, 2018	SELL	$2.26 - $3.27 $483 - $699	-214 Reduced 0.37%	58,076 $186,000
Q2 2018 Aug 14, 2018	BUY	$3.02 - $4.94 $110,435 - $180,645	36,568 Added 168.35%	58,290 $176,000
Q4 2017 Feb 14, 2018	SELL	$4.0 - $6.54 $53,948 - $88,204	-13,487 Reduced 38.31%	21,722 $90,000
Q3 2017 Nov 13, 2017	SELL	$4.99 - $6.57 $249 - $328	-50 Reduced 0.14%	35,209 $216,000
Q2 2017 Aug 14, 2017	BUY	N/A	35,259	35,259 $219,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account